8-KEarnings & ResultsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Financial Results (Oct 23, 2014)

Filed October 23, 2014For Securities:EW

Summary

This 8-K filing by Edwards Lifesciences Corporation (EW) reports on their financial results for the third quarter of 2014. The company issued a press release on October 23, 2014, detailing these results. While the 8-K itself does not provide the specific financial figures, it directs investors to the attached press release (Exhibit 99.1) for comprehensive information on revenue, earnings, and other key performance indicators for the quarter ended September 30, 2014. For investors, this filing serves as an official notification of the company's performance during the period. It's crucial to review the referenced press release to understand the company's operational and financial health, including any forward-looking statements or guidance that may have been provided. The Chief Financial Officer, Scott B. Ullem, signed off on this report, indicating its official release and adherence to reporting requirements.

Key Highlights

  • 1Edwards Lifesciences Corporation filed an 8-K on October 23, 2014.
  • 2The filing pertains to the company's financial results for the third quarter of 2014.
  • 3The detailed financial results are provided in a press release, Exhibit 99.1, attached to the filing.
  • 4The press release is dated October 23, 2014, the same day as the filing.
  • 5The information furnished under Item 2.02 is not considered 'filed' for certain regulatory purposes, but is provided for investor awareness.
  • 6The report was signed by Scott B. Ullem, Corporate Vice President and Chief Financial Officer.

Frequently Asked Questions

The main purpose of this 8-K filing is to report Edwards Lifesciences Corporation's financial results for the third quarter of 2014. The specific details of these results are contained within a press release attached as Exhibit 99.1.

The actual financial numbers and detailed commentary for Edwards Lifesciences' third quarter 2014 results can be found in the press release, Exhibit 99.1, which is incorporated by reference into this 8-K filing.

Scott B. Ullem is the Corporate Vice President and Chief Financial Officer of Edwards Lifesciences Corporation. His signature on the 8-K filing indicates that the company is officially releasing this information and that it has been reviewed and authorized by a senior financial executive.

While this 8-K filing itself doesn't contain forward-looking statements, the accompanying press release (Exhibit 99.1) often includes such information. Investors should carefully review the press release for any forward-looking statements, guidance, or risk factors related to the company's future performance.